Effective dose evaluation for 18F cis-FPro using ICRP reference phantoms

Document Type : Original Article

Authors

Faculty of Physics, University of Guilan, Namjoo avenue, Rasht, Guilan, Iran

Abstract

Cis-4-[18F]fluoro-L-proline is one of the 18F-labelled amino acids which can be used as a tracer to identify abnormal collagen synthesis rates. This study aims to estimate the absorbed and effective dose of this radiopharmaceutical using ICRP reference phantoms and the ICRP 103 tissue weight factors, which have not been done so far. For this purpose, the MIRD method was used to estimate the absorbed dose of organs. The data relating to the distribution of this radiopharmaceutical in the body were taken from a previously published study. Also, the absorbed dose and effective doses were calculated for revised ORNL phantoms to validate and compare the results. The effective dose coefficient of this radiopharmaceutical using the tissue weighting factors of ICRP 103 is 1.52E-02 mSv/MBq. The kidneys receive the highest absorbed dose after the injection of this radiopharmaceutical. For a given administered activity, this radiopharmaceutical leads to a lower effective dose to the patients than FDG.

Keywords

References

1. H. J. Wester, M. Herz, W. Weber, P. Heiss, R. Senekowitsch-Schmidtke, M. Schwaiger, G. Stocklin, Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J. Nucl. Med. 40 (1) (1999) 205-212.
2. H. J. Biersack, H. H. Coenen, , G. Stocklin, K. Reichmann, A. Bocjisch, P. Oehra, M. Kashab, O. Rollmann, Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. J. Nucl. Med. 30 (1) (1989) 110-112.
3. T. Inoue, K. Tomiyoshi, K. Ahmed, M. Sarwar, K. Aoyagi, S. Amano, S. Alyafei, H. Zhang, K. Endo. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J. Nucl. Med. 39 (4) (1998) 663-667.
4. T. Ogawa, S. Miura, M. Murakami, H. Iida, J. Hatazawa, A. Inugami, I. Kanno, N. Yasui, T. Sasajima, K. Uemura. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur. J. Nucl. Med. 23 (8) (1996) 889-895.
5. A. R. Börner, K. J. Langen, H. Herzog, K. Hamacher, V. Muller-Matteis, T. Schmitz, R. Ackermann, H. H. Coenen. Whole-body kinetics and dosimetry of cis-4-[18F]fluoro-l-proline. Nucl. Med. Biol. 28 (3) (2001) 287-292.
6. W. E. Bolch, K. F. Eckerman, G. Sgouros, S. R. Thomas. A generalized schema for radiopharmaceutical dosimetrystandardization of nomenclature, MIRD pamphlet No. 21. J. Nucl. Med. 50 (3) (2009) 477-484.
7. ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18 (1988).
8. ICRP. Radiation Dose to Patients from Radiopharmaceuticals, ICRP Publication 80 (Addendum 2 to ICRP Publication 53). Ann. ICRP 28 (1998).
9. ICRP. Radiation Dose to Patients from Radiopharmaceuticals, ICRP publication 106 (Addendum 3 to ICRP Publication 53). Ann. ICRP 38 (2008).
10. ICRP. Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. ICRP Publication 128. Ann. ICRP 44 (2015).
11. ICRP. Adult Reference Computational Phantoms. ICRP Publication 110. Ann. ICRP 39 (2009).
12. ICRP. Basic anatomical and physiological data for use in radiological protection: reference values, ICRP Publication
89. Ann. ICRP 32 (3-4) (2002).
13. M. Cristy, K. F. Eckerman. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM 8381/V 1-7, Oak Ridge, TN: Oak Ridge National Laboratory (1987).
14. E. Y. Han, W. E. Bolch, K. F. Eckerman. Revisions to the ORNL series of adult and pediatric computational phantoms for use with the MIRD schema. Health Phys. 90 (4) (2006) 337-356.
15. A. Sadre Momtaz, F. Safarnejad, InRaDoS: An internal radiation dosimetry computer program, Iranian J. Nucl. Med. 29 (2) (2021) 79-85.
16. A. Sadre Momtaz, F. Safarnejad, Effective Dose to Adult Patients Undergoing Renal Scans With 99MTC (DMSA, DTPA, EC and MAG3). Radiation Protection Dosimetry (2022).
17. W. S. Snyder, M. R. Ford, G. G. Warner, S. B. Watson. A tabulation of dose equivalent per microcurie-day for source and target organs of an adult for various radionuclides. ORNL-5000, Oak Ridge, TN: Oak Ridge National Laboratory (1974).
18. ICRP. 1990 Recommendations of the International Commission on Radiological Protection. Ann. ICRP, 21 (1-3) (1991) 1-201.
19. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann. ICRP 37 (2-4) (2007) 1-332.
20. L. Hadid, A. Gardumi, A. Desbrée, Evaluation of absorbed and effective doses to patients from radiopharmaceuticals
using the ICRP 110 reference computational phantoms and ICRP 103 formulation. Radiat. Prot. Dosimetry 156 (2) (2013) 141-159.
21. M. Andersson, L. Johansson, D. Minarik, S. Leide-Svegborn, S. Mattson, Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys. 1 (1) (2014) 9.

Files

Share

How to cite

Statistics